Attralus Employee Directory
Biotechnology ResearchFlorida, United States11-50 Employees
Attralus is a clinical-stage biotechnology company based in Naples, Florida, focused on developing medicines for systemic amyloidosis. Its approach centers on pan-amyloid removal therapeutics that bind to and eliminate toxic amyloid deposits from organs and tissues, with the aim of addressing the disease’s root pathology across all types and stages of systemic amyloidosis. The company serves clinicians and patients affected by systemic amyloidosis, offering a therapeutic concept intended to alter disease progression by removing amyloid from affected sites. In May 2026, Bayer AG acquired iodine-124 evuzamitide (AT-01) from Attralus, a move aligned with Bayer’s strategy to broaden its radiology portfolio for precision imaging in cardiovascular disease and other serious conditions.